论文部分内容阅读
近年来非霍奇金淋巴瘤(NHL)的发病率呈逐渐上升趋势。弥漫大B细胞淋巴瘤(DLBCL)是NHL中最主要的亚型,约占NHL的30%,复发率和病死率较高,临床有效率70%,治愈困难;利妥西单抗(美罗华注射液)是通过基因重组技术生产的一种人鼠嵌合的抗CD20单克隆抗体,自从1997年美国食品和药品管理局批准将利妥昔单抗应用于CD20阳性的B细胞NHL的治疗以来,已显示出卓越的疗效。国外研究表明美罗华联合
In recent years, the incidence of non-Hodgkin’s lymphoma (NHL) showed a gradual upward trend. Diffuse large B-cell lymphoma (DLBCL) is the most important subtype in NHL, accounting for about 30% of NHL. The relapse rate and mortality rate are high, the clinical effective rate is 70%, which makes it difficult to cure. Rituxan (Rituximab ) Is a human-mouse chimeric anti-CD20 monoclonal antibody produced by genetic recombination technology. Since the FDA approved the Rituximab treatment for CD20-positive B cell NHL in 1997, Shows excellent efficacy. Foreign studies show that Rituximab